These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24361757)

  • 21. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.
    Staerk L; Gislason GH; Lip GY; Fosbøl EL; Hansen ML; Lamberts M; Bonde AN; Torp-Pedersen C; Olesen JB
    Europace; 2015 Aug; 17(8):1215-22. PubMed ID: 25995392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of bleeding with dabigatran in atrial fibrillation.
    Hernandez I; Baik SH; Piñera A; Zhang Y
    JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM
    Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
    Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
    Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation.
    Avgil Tsadok M; Jackevicius CA; Rahme E; Humphries KH; Pilote L
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):593-9. PubMed ID: 26508666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
    Ali A; Bailey C; Abdelhafiz AH
    Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation.
    Salazar CA; del Aguila D; Cordova EG
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD009893. PubMed ID: 24677203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
    Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
    Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
    Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Go AS; Singer DE; Toh S; Cheetham TC; Reichman ME; Graham DJ; Southworth MR; Zhang R; Izem R; Goulding MR; Houstoun M; Mott K; Sung SH; Gagne JJ
    Ann Intern Med; 2017 Dec; 167(12):845-854. PubMed ID: 29132153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
    Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
    Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin-A Nationwide Cohort Study.
    Pallisgaard JL; Lindhardt TB; Hansen ML; Schjerning AM; Olesen JB; Staerk L; Torp-Pedersen C; Gislason GH
    PLoS One; 2015; 10(10):e0141377. PubMed ID: 26513589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
    Szapary L; Fehér G; Bosnyák E; Deli G; Csécsei P
    Ideggyogy Sz; 2013 May; 66(5-6):165-74. PubMed ID: 23909016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Zint K; Schneeweiss S
    Thromb Haemost; 2015 Nov; 114(6):1277-89. PubMed ID: 26446507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
    Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.